NASDAQ · Biotechnology

ERYTECH Pharma S.A. (ERYP) Stock

$0.78 +1.30% NASDAQ: ERYP Healthcare

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases.

Valuation

MetricValue
Price$0.78
Market Cap$47.38M
P/E Ratio-92.19
P/B Ratio0.90
P/S Ratio0.00
EPS (TTM)$-0.01
52-Week High$1.47
52-Week Low$0.30
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-0.98%
ROA-0.50%
ROCE-8.19%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.58
Current Ratio3.65

Annual Financials (USD)

Metric20182019202020212022
Revenue$4.0M$3.0M$0$0$0
Operating Profit$4.0M$5.0M$-69.0M$-57.0M$-3.0M
Net Profit$-38.0M$-63.0M$-73.0M$-54.0M$0
EPS$-2.13$-3.49$-3.99$-2.27$-0.01
Op Margin107.5%157.1%———

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$168.0M$119.0M$80.0M$67.0M$46.0M
Total Liabilities$22.0M$33.0M$54.0M$44.0M$22.0M
Cash$134.0M$73.0M$44.0M$34.0M$39.0M
Borrowings$2.0M$14.0M$27.0M$25.0M$14.0M

Latest News

Vallourec to supply pipes for Atapu 2 offshore project in Brazil Offshore Technology · Jul 23, 2026 Micron and Sandisk Are Surging: Can the Rally Last Through 2027? Motley Fool · Jul 23, 2026 1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds StockStory · Jul 23, 2026 CRIF India Launches Chennai Chapter of 'Credit Goes to HER' to Strengthen Women's Leadership in the Credit Ecosystem PR Newswire · Jul 23, 2026 Net Asset Value(s) Business Wire · Jul 23, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-39.0M$-43.0M$-52.0M$-57.0M$-32.0M
Investing Cash Flow$-29.0M$-40.0M$-3.0M$-1.0M$38.0M
Financing Cash Flow$-1.0M$0$25.0M$45.0M$-2.0M
Net Cash Flow$-51.0M$-61.0M$-29.0M$-11.0M$5.0M
Free Cash Flow$-53.0M$-63.0M$-53.0M$-57.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.27
EV / EBITDA3.55
FCF Yield-76.85%
Quick Ratio3.54
Interest Coverage-2.05
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALVRAlloVir, Inc. $9.81 +4.14% -1.89 $49.48M 0.00%
BLUEbluebird bio, Inc. $4.97 — -0.20 $48.67M 0.00%
CERCCerecor Inc. $2.93 -1.68% -0.53 $38.63M 0.00%
GRNAGreenLight Biosciences Holdings $0.30 -0.03% -0.24 $45.43M 0.00%
KRONKronos Bio, Inc. $0.88 +1.49% -0.62 $53.65M 0.00%

About ERYTECH Pharma S.A.

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.

ERYTECH Pharma S.A. is headquartered in FR.

ERYTECH Pharma S.A. (ERYP) stock trades at $0.78 with a market capitalization of $47.38M. The stock is valued at a negative price-to-earnings (P/E) ratio of -92.19, reflecting a net loss over the last twelve months, price-to-book of 0.90, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.30 and $1.47, and currently trades 46.9% below its 52-week high.

On profitability, ERYTECH Pharma S.A. generates a return on equity (ROE) of -0.98% (negative, reflecting a net loss), return on capital employed of -8.19%.

Official website: www.erytech.com

Related Healthcare Stocks

LLY Eli Lilly and Company $1211.40 +3.85% JNJ Johnson & Johnson $253.91 +2.13% ABBV AbbVie Inc. $283.52 +3.34% MRK Merck & Company, Inc. Common Stock (new) $147.37 +3.79% UNH UnitedHealth Group Incorporated Common Stock (DE) $395.62 +4.73% NVS Novartis AG $146.88 +3.14% AZN AstraZeneca PLC $162.03 +3.99% TMO Thermo Fisher Scientific Inc $673.20 +1.53% AMGN Amgen Inc. $426.11 +3.21% GILD Gilead Sciences, Inc. $153.54 +3.80% ABT Abbott Laboratories $102.97 +0.35% NVO Novo Nordisk A/S $38.12 +0.16%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.